Literature DB >> 24880792

Idiopathic pleuroparenchymal fibroelastosis is characterized by an elevated serum level of surfactant protein-D, but Not Krebs von den Lungen-6.

Seidai Sato1, Masaki Hanibuchi, Asami Fukuya, Youhei Yabuki, Hiroki Bando, Terumi Yoshijima, Hisatsugu Goto, Hirohisa Ogawa, Yasuhiko Nishioka.   

Abstract

PURPOSE: Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a recently reported rare disease entity characterized by fibrotic thickening of the pleural and subpleural parenchyma predominantly in the upper lobes in idiopathic interstitial pneumonias (IIPs). Because the clinical features of this rare disease are not fully elucidated, we examined the clinical characteristics of IPPFE, especially for serum interstitial biomarkers, surfactant protein-D (SP-D), and Krebs von den Lungen-6 (KL-6). METHODS AND
RESULTS: Four consecutive cases of IPPFE who fulfilled the diagnostic criteria were studied. All cases were more than 60 years of age, and were classified as underweight by body mass index. A severe restrictive ventilatory defect was found in all cases on admission. High-resolution computed tomography showed intense pleural thickening associated with fibrosis predominant in upper lobes. Histopathological findings were also confirmed in three out of four cases. Interestingly, the serum level of SP-D was markedly elevated in all cases, while KL-6 was within normal range in three out of four cases. As compared with major IIPs such as idiopathic pulmonary fibrosis and fibrotic nonspecific interstitial pneumonia, IPPFE significantly showed higher frequency of cases with a unique pattern of serum biomarkers, which is characterized by an elevated level of SP-D with a normal range of KL-6.
CONCLUSIONS: In IPPFE, SP-D might tend to be elevated, while KL-6 was within a normal range. Further study is required to determine the pathogenesis and clinical significance of the elevated SP-D in IPPFE.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24880792     DOI: 10.1007/s00408-014-9599-0

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  16 in total

1.  New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6.

Authors:  N Kohno; S Kyoizumi; Y Awaya; H Fukuhara; M Yamakido; M Akiyama
Journal:  Chest       Date:  1989-07       Impact factor: 9.410

2.  Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.

Authors:  Hiroshi Ohnishi; Akihito Yokoyama; Keiichi Kondo; Hironobu Hamada; Masahiro Abe; Kazutaka Nishimura; Kunio Hiwada; Nobuoki Kohno
Journal:  Am J Respir Crit Care Med       Date:  2002-02-01       Impact factor: 21.405

3.  Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes.

Authors:  Taryn L Reddy; Masaki Tominaga; David M Hansell; Jan von der Thusen; Doris Rassl; Helen Parfrey; Suzy Guy; Orion Twentyman; Alexandra Rice; Toby M Maher; Elisabetta A Renzoni; Athol U Wells; Andrew G Nicholson
Journal:  Eur Respir J       Date:  2012-03-22       Impact factor: 16.671

4.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Authors:  Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Marilyn K Glassberg; David Kardatzke; Talmadge E King; Lisa Lancaster; Steven A Sahn; Javier Szwarcberg; Dominique Valeyre; Roland M du Bois
Journal:  Lancet       Date:  2011-05-13       Impact factor: 79.321

5.  Rapid decrease in forced vital capacity in patients with idiopathic pulmonary upper lobe fibrosis.

Authors:  Kentaro Watanabe; Nobuhiko Nagata; Yasuhiko Kitasato; Kentaro Wakamatsu; Kazuki Nabeshima; Taishi Harada; Takako Hirota; Motokimi Shiraishi; Masaki Fujita
Journal:  Respir Investig       Date:  2012-08-01

6.  Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis.

Authors:  K E Greene; T E King; Y Kuroki; B Bucher-Bartelson; G W Hunninghake; L S Newman; H Nagae; R J Mason
Journal:  Eur Respir J       Date:  2002-03       Impact factor: 16.671

Review 7.  Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.

Authors:  Amrita Dosanjh
Journal:  Eur J Pharmacol       Date:  2006-03-14       Impact factor: 4.432

8.  Immunohistochemical distribution of SP-D, compared with that of SP-A and KL-6, in interstitial pneumonias.

Authors:  Yuji Ohtsuki; Norihiko Nakanishi; Jiro Fujita; Takeo Yoshinouchi; Makoto Kobayashi; Nobuo Ueda; Gang-Hong Lee; Mutsuo Furihata
Journal:  Med Mol Morphol       Date:  2007-09-18       Impact factor: 2.309

9.  Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma.

Authors:  N Kohno; M Akiyama; S Kyoizumi; M Hakoda; K Kobuke; M Yamakido
Journal:  Jpn J Clin Oncol       Date:  1988-09       Impact factor: 3.019

10.  Idiopathic pleuroparenchymal fibroelastosis: consideration of a clinicopathological entity in a series of Japanese patients.

Authors:  Hideki Kusagaya; Yutaro Nakamura; Masato Kono; Yusuke Kaida; Shigeki Kuroishi; Noriyuki Enomoto; Tomoyuki Fujisawa; Naoki Koshimizu; Koshi Yokomura; Naoki Inui; Takafumi Suda; Thomas V Colby; Kingo Chida
Journal:  BMC Pulm Med       Date:  2012-12-05       Impact factor: 3.317

View more
  6 in total

1.  Idiopathic pleuroparenchymal fibroelastosis, a new idiopathic interstitial pneumonia: A case report.

Authors:  Enrique Javier Soto Hurtado; Maria Luisa Amaya González; Maria Del Mar Elena Soto; Francisco Jose Cabello Rueda; Francisco Javier Pérez Nadal; Alberto Ruíz Cantero
Journal:  Chron Respir Dis       Date:  2016-01-25       Impact factor: 2.444

Review 2.  The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Hiroshi Ishii; Kazuki Nabeshima; Kentato Watanabe
Journal:  Histol Histopathol       Date:  2020-12-14       Impact factor: 2.303

Review 3.  Idiopathic Pleuroparenchymal Fibroelastosis.

Authors:  Martina Bonifazi; M Angeles Montero; Elisabetta A Renzoni
Journal:  Curr Pulmonol Rep       Date:  2017-01-27

4.  Series of rare lung diseases mimicking imaging patterns of common diffuse parenchymal lung diseases.

Authors:  Kiran Batra; Riham Dessouky; Yasmeen M Butt; Vibhor Wadhwa; Jose R Torrealba; Craig Glazer
Journal:  Lung India       Date:  2018 May-Jun

5.  Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage.

Authors:  Makoto Shioya; Mitsuo Otsuka; Gen Yamada; Yasuaki Umeda; Kimiyuki Ikeda; Hirotaka Nishikiori; Koji Kuronuma; Hirofumi Chiba; Hiroki Takahashi
Journal:  Can Respir J       Date:  2018-08-13       Impact factor: 2.409

6.  Clinical significance of radiological pleuroparenchymal fibroelastosis pattern in interstitial lung disease patients registered for lung transplantation: a retrospective cohort study.

Authors:  Kiminobu Tanizawa; Tomohiro Handa; Takeshi Kubo; Toyofumi F Chen-Yoshikawa; Akihiro Aoyama; Hideki Motoyama; Kyoko Hijiya; Akihiko Yoshizawa; Yohei Oshima; Kohei Ikezoe; Shinsaku Tokuda; Yoshinari Nakatsuka; Yuko Murase; Sonoko Nagai; Shigeo Muro; Toru Oga; Kazuo Chin; Toyohiro Hirai; Hiroshi Date
Journal:  Respir Res       Date:  2018-08-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.